Physicians' Academy for Cardiovascular Education

Novel strategies targeting residual risk: The promise of PCSK9 inhibiting therapies

10' education - Aug. 28, 2016 - ESC 2016, Rome - Erik Stroes, MD – Academic Medical Center, Amsterdam, The Netherlands - PACE-CME symposium held at ESC 2016 in Rome

This lecture was part of a CME accredited symposium: How to address residual risk post ACS: LDL-c, dyslipidemia, and inflammation held at ESC 2016 in Rome

Video navigation menu

  • Why LDL-C as target to reduce residual risk? 00:14
  • Why do we need further LDL-C lowering therapies? 02:32
  • The promise of PCSK9-inhibiting therapies 03:55
  • Ongoing phase III trials with PCSK9 inhibitors including ACS patients 09:45
  • The relation between PCSK9 inhibition and inflammation 10:10
  • Take home messages 13:48

Educational information

The educational objectives of this symposum were to:


Prof. Erik Stroes, MD: - Chairman, Department of Vascular Medicine, Academic Medical Center, University of Amsterdam - Amsterdam, The Netherlands


This EBAC accredited symposium was funded by unrestricted educational grants received from Novartis, MSD, Amgen

View slides of this lecture

The content is aimed for medical professionals. To view this item member registration is needed. Register for free to get unlimited access to our educational resources.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: